SHR4640
Sponsors
Jiangsu HengRui Medicine Co., Ltd., Atridia Pty Ltd.
Conditions
GoutGout; HyperuricemiaHealthy SubjectsHepatic ImpairmentHyperuricemiaPrimary GoutPrimary Gout and Hyperuricemia
Phase 1
Single Dose Study of SHR4640 in Healthy Subjects
CompletedNCT02815839
Start: 2015-11-30End: 2017-02-28Updated: 2017-02-28
Multiple Dose Study of SHR4640 in Healthy Subjects
CompletedNCT02890966
Start: 2016-07-31End: 2017-03-31Updated: 2017-03-30
A Single Dose Study of SHR4640 in Healthy Male Volunteers
CompletedNCT03015948
Start: 2016-09-22End: 2016-11-23Updated: 2018-07-03
The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout
CompletedNCT03131583
Start: 2017-02-17End: 2018-01-29Updated: 2019-08-08
Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level
CompletedNCT03211403
Start: 2017-07-04End: 2018-02-15Updated: 2018-03-21
Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment
NCT04305392
Start: 2020-08-04End: 2022-12-31Updated: 2022-08-10
Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers
NCT04586803
Start: 2020-10-31End: 2020-12-31Target: 24Updated: 2020-10-14
Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers
NCT04620408
Start: 2020-12-31End: 2021-02-28Target: 14Updated: 2020-11-09
Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects
CompletedNCT05954169
Start: 2023-08-07End: 2024-07-01Updated: 2024-07-11
Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects
CompletedNCT06168929
Start: 2023-12-13End: 2024-01-13Updated: 2024-01-23
Phase 2
Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia
CompletedNCT03185793
Start: 2017-07-20End: 2018-07-20Updated: 2019-08-07
The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
RecruitingNCT07362355
Start: 2026-02-09End: 2027-07-01Target: 340Updated: 2026-04-07